Clınıcal Sıgnıfıcance of HDL-C Values And Routıne Parameters Of Inflammatıon Such As Hs-Crp, Lenfocyte And Neutrofıl Ratıos In Covıd-19 Patıents

Abstract

Objective: The study aimed to evaluate the prognostic significance of high-density lipoprotein cholesterol (HDL-C) levels, alongside markers including the neutrophil/HDL-C ratio (NHR) and lymphocyte/HDL-C ratio (LHR), on the mortality of COVID-19 patients. It also examined the potential clinical application of these biomarkers in the management of future healthcare crises, despite the end of the COVID-19 pandemic. Materials and Methods: Patients diagnosed with COVID-19 were retrospectively analysed between March 2020 and August 2022. A total of 367 patients were categorised into two groups: survivors (group 2) and non-survivors (group 1). Patient demographics, biochemical and haematological parameters obtained from blood samples, high-sensitivity C-reactive protein (hs-CRP), neutrophil-to-lymphocyte ratio (NLR), monocyte/HDL-C ratio (MHR), NHR, LHR, platelet/HDL-C ratio (PHR) were calculated. Patient data were analysed using SPSS 26 and statistical differences of P<0.05 were considered significant. Results: Among the patients analyzed in the study, the living group constituted 89.9% of individuals, while the deceased group represented 10.1%. The neutrophil levels were significantly higher in the deceased group, and NLR and NHR values were statistically significant (P<0.001 and P=0.001, respectively). There was no significant difference in HDL-C levels. Moreover, no significant differences in LHR, MHR, and PHR levels were observed between groups. The hs-CRP levels were significantly higher in the deceased (P<0.001). Correlation analysis indicated a negative correlation between HDL-C and LHR and NHR, and significant correlations were found for other markers. ROC analysis showed that LHR and NHR were significant in discriminating deceased patients. Conclusion: Biochemical and haematological parameters, especially markers such as NLR and NHR, can potentially be used to assess the risk of death in COVID-19 patients. These markers may be valuable in predicting the prognosis of patients and could be used in future similar health crises.